Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS Health (CVS) is maintaining Thursday gains ahead of the closing bell after outpacing top and bottom line expectations, ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...